In all the hoopla over the new FDA funding-and-reform legislation last month, a key provision was eclipsed--the creation of a new research center paid for by drug makers. The Reagan-Udall Foundation is designed to streamline and improve drug development. But as the Associated Press notes, a research collaboration yoking pharma with the FDA creates an entirely new form of regulator-regulatee relationship--one that might get drugs to market more quickly and more cheaply, but even less safely.
The FDA is fast-tracking nominations to the new center's board, with members slated to be named by October 27. Four of the fourteen members are expected to be pharma executives.
FDA, Big Pharma collaborate on genetic tests. Report
House overhauls, passes PDUFA. Report
Bickering may stall trial database. Report
PDUFA debate highlights drug safety issues. Report
Read more on: FDA news